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Neural tube defects (NTDs) affecting the brain (anencephaly) are lethal before or at birth,
whereas lower spinal defects (spina bifida) may lead to lifelong neurological handicap. Collec-
tively, NTDs rank among the most common birth defects worldwide. This study focuses on
anencephaly, which despite having a similar frequency to spina bifida and being the most com-
mon type of NTD observed in mouse models, has had more limited inclusion in genetic studies.
A genetic influence is strongly implicated in determining risk of NTDs and a molecular diagnosis
is of fundamental importance to families both in terms of understanding the origin of the con-
dition and for managing future pregnancies. Here we used a custom panel of 191 NTD candi-
date genes to screen 90 patients with cranial NTDs (n = 85 anencephaly and n = 5
craniorachischisis) with a targeted exome sequencing platform. After filtering and comparing to
our in-house control exome database (N = 509), we identified 397 rare variants (minor allele
frequency, MAF < 1%), 21 of which were previously unreported and predicted damaging. This
included 1 frameshift (PDGFRA), 2 stop-gained (MAT1A; NOS2) and 18 missense variations.
Together with evidence for oligogenic inheritance, this study provides new information on the
possible genetic causation of anencephaly.
KEYWORDS
anencephaly, craniorachischisis, molecular diagnosis, neural tube defects, targeted exome
sequencing
1 | INTRODUCTION
Neural tube defects (NTDs) are a group of anomalies in which closure
of the future brain and/or spinal cord of the developing embryo is
abnormal, resulting in a birth defect. Collectively, they rank among
the most common human birth defects worldwide with a prevalence
of 0.5 to 2 per 1000 pregnancies. NTDs can be broadly divided into
primary and secondary neurulation defects.1 The former group are
evenly split between anencephaly, in which the cranial neural tube
fails to close exposing the mid and hind brain region and spina bifida
aperta where the low spinal neural tube remains open. Much more
rarely the neural folds remain open along the entire body axis, which is
called craniorachischisis. Anencephaly and craniorachischisis result in
stillbirth or infant mortality, while spinal defects can be associated with
lifelong neurological disability. It is important to note that approxi-
mately 85% of open NTD cases in the United Kingdom are termi-
nated.2 Given the high prevalence and traumatic consequences for
affected individuals and their families, the identification of the precise
genetic, biochemical and cellular factors involved is a high priority.
NTDs are generally considered multifactorial with both genetic
and environmental factors implicated in their etiology. Although most
NTDs occur sporadically, there is a strong genetic component with a
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heritability estimate of up to 70%.3 Despite this, the molecular basis
in humans has proven difficult to resolve. This may be attributed to
the high degree of heterogeneity between unrelated sporadic cases,
incomplete penetrance and the general paucity of large individual
families displaying Mendelian inheritance. The complex molecular
requirements for normal neural tube closure are well illustrated by
the occurrence of NTDs in more than 200 different mouse genetic
models.4
It has been estimated that up to 70% of potential NTD cases
are preventable by the mother taking periconceptional supplements
of folic acid.5,6 However, evidence for causal mutations in genes
regulating folate metabolism remain tenuous.7 In humans, planar cell
polarity (PCP) gene variants have been reported in heterozygous
form throughout the NTD phenotypic spectrum. When tested, these
variants are mostly found in an unaffected parent, prompting specu-
lation regarding incomplete penetrance effects, which may be
explained by co-inheritance of additional variants in other closely
related or interacting genes that remain undetected using the method-
ologies employed.8 This genetic interaction is evident in NTD mouse
models doubly heterozygous for PCP genes,9 suggesting that a compre-
hensive study of PCP genes in humans would be a valuable exercise.
The patient cohorts in most candidate gene studies contain
mixed primary and secondary neurulation phenotypes, typically
including only a small number of craniorachischisis or anencephalic
cases. There is therefore a relative lack of information concerning the
genetic basis of anencephaly in humans. In contrast, exencephaly, the
developmental forerunner of anencephaly, is present in more than
90% of mouse mutants that transmit NTDs in a Mendelian fashion. It
is also striking that the primary folate-sensitive NTD in mouse models
is exencephaly, with less supporting evidence for primary prevention
of mouse spina bifida by folic acid supplementation.4,10,11 Even so, it
is clear that both anencephaly and spina bifida can be prevented by
folic acid in humans.5,12 In addition, there is a marked excess in
females in anencephaly and craniorachischisis compared to spina
bifida.1 Collectively, these data might suggest that genetic factors
implicated in anencephaly and craniorachischisis could be different
from those implicated in spina bifida cases.
In this study, we have carried out a comprehensive, targeted
exome sequencing of fetuses with anencephaly using a panel of
191 genes with biological relevance to NTDs. Unlike the traditional
gene-by-gene search method, this allowed us to test the hypothesis
that multiple hits in different, but closely related genes may combine
to provide an oligogenic explanation for NTD risk.
2 | MATERIALS AND METHODS
2.1 | NTD and healthy control human DNA samples
The sample group for this study comprised 85 fetuses with anen-
cephaly and 4 with craniorachischisis that underwent pregnancy ter-
mination following prenatal diagnosis by ultrasound in the north east
of England between 1992 and 2011. Although folic acid supplements
were recommended from 1991 onwards there was no mandatory
folate fortification of food for this population and folic acid
supplement use, typically 400 μg/day, has been estimated to have an
uptake of up to around 30%.13 Fibroblast samples were collected by
the Northern Genetics Service following signed consent and
approved for research under The Newcastle Upon Tyne Hospitals
NHS Trust Ethical Committee. DNA was extracted from fetal fibro-
blasts using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Ger-
many) following the manufacturer’s protocol. One further
craniorachischisis sample obtained from Hammersmith Hospital,
London, UK was also included, making a total of 90 NTD samples. No
parental samples were available for the NTD cases. Control DNA
samples were extracted from whole blood obtained from 6 healthy
white Europeans (2 trios) in the Moore cohort.14 The samples were
collected under the guidelines of the Hammersmith and Queen Char-
lotte’s and Chelsea Hospitals’ NHS Trusts Research Ethics Committee
(registration no. 2001/6029).
2.2 | Selection of NTD candidate genes
The targeted gene panel for NTDs included 191 genes that were
selected by one of several criteria. These included genes that encode
enzymes of folate one-carbon metabolism or components of the PCP
or related cell polarity pathways that are implicated in normal neuru-
lation in animal models. Additional members of these pathways were
added even where a role in neurulation has not yet been directly indi-
cated and also multiple gene family members, for example, CELSR1,
CELSR2 and CELSR3, irrespective of whether there was a prior estab-
lished link with NTDs. The panel design also included a number of
prominent genes underlying NTDs in well-studied mouse models (eg,
PAX3 and ZIC3; see gene panel list in Table S1 in Appendix S3, Sup-
porting information).
2.3 | Target enrichment library preparation and
sequencing
Custom capture libraries were generated from 3 μg gDNA using the
SureSelectXT Reagent kit (Agilent Technologies, Santa Clara, Califor-
nia). RNA baits (Table S1 in Appendix S3) were designed using Sure-
Design (Agilent Technologies), with an estimated average coverage of
98.2% of targeted regions. Samples were sequenced with MiSeq
Reagent kit v3 (150 cycle; 2 × 75 bp) on the MiSeq Sequencing Sys-
tem (Illumina, San Diego, California).
2.4 | Sequence alignment, variant annotation and
filtering
An in-house pipeline was used for the sequence alignment, variant
calling and annotation. FASTQ files were trimmed with Cutadapt15
and the sequencing reads were aligned to the human reference
genome (hg19) using the Burrows-Wheeler Aligner (v0.6.1-r104)16.
SAMtools (v0.1.18)17 was used to generate mpileup files for vari-
ant calling with VarScan2 (v2.3.6)18 to generate VCF files. Only
variants with >30 read depths, >0.2 variant frequency, and average
quality score of >20 were called. Candidate variants were manually
checked on the integrative genomics viewer. Principal component
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analysis was used to assess sample relatedness (Methods in
Appendix S2).
2.5 | Variant filtering and prioritization
Variants were annotated with Ensembl Variant Effect Predictor (v73:
http://www.ensembl.org/info/docs/tools/vep/index.html). Provean,19
SIFT,20 PolyPhen2,21 Condel,22 REVEL23 and MutationTaster24 were
used for predicting the effects of variants. REVEL score >0.5 were
used as threshold for classifying pathogenic variants. Intronic, synon-
ymous, 30 and 50 UTR, up- and downstream variants were removed.
Rare variants were defined as minor allele frequency (MAF) <1% in
the Exome Aggregation Consortium (ExAC) Database.25 Variants that
were specific to NTD patients and not present in the capture control
(N = 6), in-house exome controls (N = 509) and in the dbSNP,26 1000
Genomes Project,27 ExAC, and the Genome Aggregation Database
(gnomAD)25 were labeled “Novel,” and were verified by Sanger
sequencing (Methods in Appendix S2).
2.6 | Mutation burden analysis
The burden of carrying multiple rare/novel variants within the
191 candidate genes was compared between the NTD and the ExAC
cohorts. To allow an unbiased gene-level comparison, the sequencing
coverage of the targeted regions was analyzed between the 2 cohorts.
The exon coordinates for the canonical transcripts of all 191 genes
were extracted as a Browser Extensible Data (BED) file from the Uni-
versity of California Santa Cruz (UCSC) database, which was used as
the reference sequence for target regions. The percentage coverage
of the targeted bases at ≥×30 read depths was calculated using
Picard (http://broadinstitute.github.io/picard/) for the NTD samples,
and the coverage information for the ExAC data was downloaded
from the ExAC database. The gene-level coverage between the
cohorts was compared using Student’s t test (2-tailed). Because
the sample-level information is not available at the ExAC database,
the number of each variant was compared in the burden analysis for
consistency as described in D’Alessandro et al.28 Only rare/novel var-
iants predicted to be damaging were used for further analysis. Fish-
er’s exact test (2-tailed) was used to assess the enrichment of rare/
novel variants on the genes showing comparable sequence coverage.
Bonferroni correction was performed by multiplying the each P-value
with the number of genes used in the test (n = 13).
3 | RESULTS
On average, 97.5% of bases were covered at ≥×30 read depth across
191 genes, indicating a high targeting efficiency. A mean target cov-
erage depth of ×110 was achieved with more than 96% of reads hav-
ing Phred quality score greater than Q30 (corresponds to 99.9% base
call accuracy). A total of 1380 variants, which passed quality control,
were identified of which 1359 were single nucleotide variants (SNVs)
and 21 were insertions/deletions (Indels) (Figure 1).
3.1 | Relatedness analysis
Principal component analysis identified 3 samples (52F03, 00F133
and 389F07) with higher variation than the rest of the samples which
might be suggestive of different ethnic background (Figure S1 in
Appendix S1). Apart from the healthy control trios (child-mother-
father) included in the capture sequencing, kinship analysis did not
indicate relatedness between any of the samples (Figure S2 in Appen-
dix S1), including 2 NTD cases which carried an identical extremely
rare variant in the CELSR1 gene (described below).
FIGURE 1 Flow chart showing the capture variant analysis pathway.
Following sequencing, data is processed through a pipeline which
provides quality control followed by a series of filters to identify
plausible causative variants. MAF, minor allele frequency; UTR,
untranslated region
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3.2 | Previously reported pathogenic mutations
associated with NTDs
One craniorachischisis/exomphalos sample (01F29A) was found to
carry a pathogenic missense variant (c.676G>A; p.Ala226Thr;
rs104894043) in the Sonic Hedgehog (SHH) gene, which was previ-
ously identified in an autosomal-dominant holoprosencephaly
3 (HPE3) patient (OMIM: 142945).29 HPE3 is characterized by mid-
line brain and craniofacial abnormalities, and it is possible that this
variant either contributes to the NTD, whilst other characteristics of
HPE are masked by the severity of the midline craniorachischisis/
exomphalos phenotype in this individual. One fetus with anencephaly
(735F97) carried a rare missense mutation (c.2852C>A; p.Ser951Tyr;
rs147472391) in glycine decarboxylase (GLDC), which was previously
reported as one of the causative mutated alleles in a compound het-
erozygous patient with the autosomal recessive disorder, non-ketotic
hyperglycinemia (NKH, OMIM: 605899).30 GLDC encodes a compo-
nent of the glycine cleavage system (GCS) in mitochondrial folate
one-carbon metabolism, which has previously been implicated in both
mouse and human NTDs.10,11,31,32 Another individual with anenceph-
aly (706F07) was heterozygous for a missense variant (c.200C>T; p.
Thr67Ile; rs28941785) in the cystathionine gamma-lyase (CTH) gene,
which causes cystathioninuria in a recessive form.33
3.3 | Unreported and rare variants
After filtering out intron, 30 and 50 UTR and synonymous variants, a
total of 397 rare (MAF < 1%, including novel) variants were identified
in 89/90 NTD cases from 110/191 of the panel of NTD candidate
genes. Of these, 209 variants were predicted to be damaging by at
least one of the mutation effect predictors described in Methods
(summarized in Table S2 in Appendix S3). Following an additional fil-
ter to include our in-house exomes (n = 509) and publically available
data (1000Genome, dbSNP, ExAC and gnomAD), there remained
21 novel variants that were predicted to be damaging (1 frameshift,
2 stop-gained and 18 missense; Table 1).
We identified 3 novel loss-of-function (LoF) variants. These
included a frameshift variant c.3029_3030delAG which introduces a
premature stop codon (p.Arg1011ThrfsTer4) in the platelet derived
growth factor receptor alpha (PDGFRA) gene (Figure 2A). In ExAC,
3 unique LoF variants are reported in PDGFRA with a pLI = 1, indicat-
ing extreme intolerance for LoF. Pdgfra-null mice are embryonic lethal
with severe NTDs and PDGFRA promoter haplotypes have been asso-
ciated with NTD susceptibility in humans.34,35 A stop-gain variant
c.360C>A (p.Cys120Ter) was detected in the methionine adenosyl-
transferase 1A (MAT1A) gene (Figure 2B). In ExAC, 2 unique stop-gain
LoF variants are reported in MAT1A with a pLI = 0.75. MAT1A
encodes methionine adenosyltransferase (MAT) which catalyzes the
conversion of methionine to S-adenosylmethionine (SAM), the uni-
versal methyl donor. Mutations in the MAT1A gene are reported to
cause MAT I/III deficiency, a condition characterized by persistent
hypermethioninemia not accompanied by elevated homocysteine or
tyrosine.36 Disturbance in the methionine cycle has been found to
cause NTDs in experimental models in the mouse.31 However, clinical
manifestations of MAT deficiency are variable, including no
neurological abnormalities.36 Also, a stop-gain variant c.1893C>A (p.
Tyr631Ter) was detected in the nitric oxide synthase 2 (NOS2) gene
(Figure 2C). In ExAC, 20 LoF variants are reported in NOS2 with a
pLI = 0, suggesting tolerance of LoF and low confidence of causal
effect. However, NOS2 has been previously associated with a cranial
NTD phenotype where A/G genotype of the rs4795067 SNP within
NOS2 was shown to be associated specifically with increased cranial
NTD risk.37
One individual (283F06) was heterozygous for a novel missense
variant in the catalytic N-terminal domain of the methylenetetrahy-
drofolate reductase (MTHFR) gene (c.601C>T; p.His201Tyr)
(Figure 2D), which was predicted to be damaging by all 6 mutation
predictors tested (Table 1). This individual was also heterozygous for
the common MTHFR c.677C>T variant, and also carries a rare glycine
decarboxylase (GLDC) c.2203G>T missense variant, possibly indicat-
ing a compromised FOCM in this patient. Interestingly, 2 unrelated
patients harbor an identical extremely rare (gnomAD frequency
1/276 358) missense variant (c.7549G>A; p.Val2517Met) within the
transmembrane receptor domain of the cadherin, EGF LAG seven-
pass G-type receptor 1 (CELSR1) gene, which encodes a core protein
of the PCP pathway (Figure 2E, Table S2 in Appendix S3). Heterozy-
gous missense mutations in CELSR1 gene have previously been
reported in a number of NTD patients.38–40 Two novel and 3 rare
SCRIB missense variants were identified in 5 anencephaly cases
(Table 1 and Table S2 in Appendix S3). SCRIB mutations have previ-
ously been implicated in human craniorachischisis.40 Three samples
carried more than 1 variant within the same gene: sample 01F292
had 2 rare FAT4 variants (c.739C>A; c.6607C>T), f11-278 had 1 novel
(c.8335C>G) and 1 rare (c.5587C>T) variants in CELSR3 and 693F06
had 2 rare missense variants (c.3109G>C; c.824G>A) in NOS2.
3.4 | Genes harboring multiple novel and rare
variants
In 51/191 genes we identified more than 1 novel and/or rare variants
predicted to be damaging (Table S2 in Appendix S3). To assess for
potential enrichment of rare/novel damaging variants in the NTD
cohort (N = 90) compared to the ExAC controls (N = 60 706), a muta-
tion burden analysis was carried out. To eliminate the possibility of
identifying significant enrichment differences due to sequencing cover-
age variation between the cohorts, percentage coverage of the tar-
geted regions at ≥30 read depth for all 191 genes were compared
between the NTD cases and the ExAC controls. As expected, on aver-
age NTD cases showed higher percentage coverage, due to the nature
of the targeted capture sequencing design. Therefore, further analysis
was limited to genes showing percentage differences not greater than
3.5% between the cohorts. This resulted in 13 genes that were compa-
rable to each other (97.5% in NTD cases vs 95.7% in controls; t test P-
value = 0.13, 2-tailed), and 8 of these genes (COBL, FAT4, MTRR,
PDGFRA, PRICKLE2, SALL4, TCN2 and TXN2) had at least 1 rare/novel
variant predicted to be damaging which could be used for further anal-
ysis. Using Fisher’s exact test, we identified 4 genes (COBL, FAT4,
PDGFRA and TXN2) that showed significant enrichment in the NTD
cases (Table 2). Of these, COBL and FAT4 stayed statistically significant
after the multiple test correction (Table S4 in Appendix S3).
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FIGURE 2 DNA sequence
electropherograms, protein
conservations and position of the
genetic variants in relation to the
protein domains. Protein domain
figures were created with
MutationMapper (http://www.
cbioportal.org/mutation_mapper.
jsp, v1.0.1). (A) PDGFRA frameshift
deletion mutation. I-set, immuno-
globulin I-set domain; Pkinase_Tyr,
protein tyrosine kinase. (B) MAT1A
stop-gained mutation. S-AdoMet_-
synt_N, S-adenosylmethionine syn-
thetase, N-terminal domain. S-
AdoMet_synt_M, S-
adenosylmethionine synthetase,
central domain; S-AdoMet_synt_C,
S-adenosylmethionine synthetase,
C-terminal domain. (C) NOS2 stop-
gained mutation. NO_synthase,
nitric oxide synthase, oxygenase
domain; Flavodoxin_1, flavodoxin.
FAD_binding_1, FAD binding
domain; NAD_binding_1, oxidore-
ductase NAD-binding domain.
(D) CELSR1 missense mutation.
Lam, Laminin G domain; GAIN,
GPCR-autoproteolysis inducing
(GAIN) domain; 7tm_2, 7 transmem-
brane receptors. (E) MTHFR mis-
sense mutation. MTHFR,
methylenetetrahydrofolate
reductase
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3.5 | Multiple damaging variants by samples
Finally, we investigated the possible effects of multiple gene interac-
tion within the same samples. On average, each NTD patient sample
carried 9 rare/novel variants, with approximately 3 of these variants
predicted to be damaging. In the NTD capture controls (n = 4 unre-
lated), each carried 2 novel/rare variants on average, with approxi-
mately 1.5 of these predicted to be damaging (Table S3 in Appendix
S3). Out of 90 NTD cases, 75 carried more than 1 novel/rare damag-
ing variants involving 98 candidate genes (Table S2 in Appendix S3).
As can be seen from the diversity of the genes affected, there was
no clear recurring pattern in which the same set of genes was
affected throughout the samples; rather, each case exhibited an indi-
vidually unique set of variants. However, some of the patients
showed multiple hits within PCP-associated genes. Five anencephaly
cases carried rare or novel CELSR1 missense variants, three of whom
carried additional rare potentially damaging PCP variants: 01F377
(CELSR1 c.6362G>A and PRICKLE4 c.730C>G), 2F07 (CELSR1
c.8807C>T and DVL3 c.1622C>T), 618F05 (CELSR1 c.8282C>T and
SCRIB c.3979G>A). One patient (f93-80) had a novel PTK7 missense
variant (c.655A>G) with a rare CELSR2 missense variant (c.1892C>T).
Three patients carried missense variants both in FZD and other PCP-
associated genes: 01F552 (FZD6 c.1531C>T and CELSR2 c.3800A>G),
335F07 (FZD6 c.544G>A and 2 FAT4 missense variants c.5792A>G;
c.10384A>G), and 465F99 (rare FZD1 missense variant c.211C>T and
a novel FAT4 missense variant c.10147G>A).
4 | DISCUSSION
In this study we have performed a comprehensive targeted exome
sequencing analysis of NTD candidate genes in a cohort of unrelated
fetuses with anencephaly and craniorachischisis, to identify genetic
variants associated with these disorders. Few genetic studies have
comprehensively investigated anencephaly, which may reflect the
extra difficulty of collecting samples following termination rather than
live born NTD cases, which are usually either spina bifida aperta, or
closed spinal dysraphism. We have examined 191 genes previously
implicated in either mouse or human NTDs, the majority of which
have not been previously analyzed in a large cohort of anencephaly
patients or studied for polygenic or burden effects.
4.1 | PDGFRA
A novel PDGFRA frameshift variant c.3029_3030delAG leading to
premature stop codon (p.Arg1011ThrfsTer4) was identified in an
anencephalic patient. PDGFRA is a cell-surface tyrosine kinase recep-
tor, which has an essential role in embryonic development and cell
proliferation.41 Homozygous Pdgfra mutant mice are embryonic lethal
presenting with a wavy neural tube and cranial region closure fail-
ure.34 In humans, the PDGFRA-promoter haplotype H1 was found to
confer low transcriptional activity and has been associated with
increased NTD risk.35 Therefore, it is possible that the reduced abun-
dance of PDGFRA caused by the LoF variant could have led to the
anencephaly phenotype in our patient. In addition, 2 other cases
(99F590 and 735F97) carried a rare missense variant c.236G>A (p.
Gly79Asp) in PDGFRA. Overall, these findings resulted in a nominal
significant enrichment of PDGFRA variants in NTD cases compared to
the healthy controls in the burden analysis.
4.2 | Folate one-carbon metabolism
Despite the well-documented benefits of folic acid in NTD preven-
tion, the actual mechanism of folate action is still unknown. Genes
involved in folate one-carbon metabolism (FOCM) have been studied
extensively as NTD candidates. Early reports described an association
between NTDs and a common variant c.677C>T within the MTHFR
gene in Dutch and Irish populations, although a subsequent meta-
analysis concluded that the increased NTD risk for this variant was
only present within the Irish population (reviewed in Reference 42).
Subsequently many genes encoding folate pathway enzymes, trans-
porters and receptors have been studied with mostly inconsistent
findings.7 More recently, several candidate variants were identified in
AMT and GLDC, 2 of the genes constituting the mitochondrial
GCS.10,32 In the present study, we identified a novel missense variant
affecting the catalytic domain of the MTHFR gene. This patient addi-
tionally carried the c.677C>T variant, and a rare missense variant
(c.2203G>T) in the GLDC gene. It is possible that this combination of
genotypes caused sub-optimal folate metabolism, leading to anen-
cephaly. In addition, we have identified 4 more patients (1 craniora-
chischisis and 3 anencephaly) carrying rare GLDC variants predicted
to be damaging. One patient (735F97) was heterozygous for the mis-
sense variant c.2852C>A (p.Ser951Tyr) previously reported in a
patient with NKH.30 While Mthfr-null mice do not display a NTD
TABLE 2 Mutation burden analysis result
Cases (N = 90) Controls (N = 60 706)
Gene
With
variants
Without
variants
With
variants
Without
variants
Percentage coverage at ×30
case/control 95% CI OR P-val P-adj
COBL 5 85 331 60 375 90.6/88.9 3.37-26.28 10.7 0.00015 0.00195
FAT4 13 77 1110 59 596 96.8/93.5 4.60-16.50 9.1 1.2E-08 1.56E-07
PDGFRA 2 88 156 60 550 99.9/97.6 1.04-33.35 8.8 0.02315 0.30095
TXN2 1 89 31 60 675 96.5/98.1 0.53-134.93 22.0 0.04631 0.60203
Abbreviations: CI, confidence interval; OR, Odds ratio; P-val, nominal P-values; P-adj, Bonferroni corrected P-values. Mutation burden analysis was per-
formed for the 191 genes in the panel. Genes that showed significant differences are shown. Because sample-level information is not available at the
ExAC database, the burden analysis was performed assuming that each variant serves as an independent sample. To allow unbiased selection, the gene-
level coverage between the NTD cases and ExAC control was compared using Student’s t test (2-tailed). The enrichment of the novel/rare variants pre-
dicted to be damaging were assessed using Fisher’s exact test (2-tailed).
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phenotype, Gldc deficient mice variably display NTDs and/or features
of NKH.11 We did not identify variants in other GCS genes, AMT or
GCSH, after filtering for frequency (<1% MAF) and mutation predic-
tion in our cohort.
4.3 | Gene-gene interactions and the PCP pathway
Both gene-environment and gene-gene interactions are believed to
play an important role in NTD etiology. In humans, NTD cases are
mostly sporadic and putative mutations reported to date are predomi-
nantly heterozygous, sometimes with incomplete penetrance.8 There-
fore, it has been suggested that human NTDs exhibit a polygenic or
oligogenic pattern of inheritance involving multiple heterozygous gene
mutations. Such genetic interactions are evident from the many doubly
heterozygous NTD mouse models that have been described.43
In the present study, the majority of cases (75/90) carried more
than 1 rare damaging variant, without revealing an obvious pattern of
co-inheritance. This might be partly attributed to the fact that the
analysis was conducted using a MAF <1% and damaging predictions,
which might have excluded a possible contribution of more common
alleles. Despite this, we identified 3 anencephalic fetuses that were
double heterozygotes, carrying missense variants in CELSR1 gene and
a variant in other PCP-related genes SCRIB, PRICKLE4, and DVL3. In
addition, 2 unrelated anencephalic patients carried the same,
extremely rare CELSR1 missense variant (c.7549G>A; 1/276 358 gno-
mAD). Rare variants in CELSR1 have previously been reported in both
open and closed NTD types.38–40 Two previous NTD cases have
been reported to be doubly heterozygous either for CELSR138 or
DVL2.44 Celsr1 homozygous mutant (Celsr1Crsh/Crsh) mice show
craniorachischisis,9 suggesting that the CELSR1 gene is likely to be
implicated in both human and mouse NTD etiology.
4.4 | Burden analysis
To maximize the number of the cases to be analyzed, only a small
number of controls were included in the sequencing platform. There-
fore, to perform burden analysis, the public database (ExAC) was
used. However, because of the lack of similarity in the sequence cov-
erage in many of the genes between the NTD and control cohorts,
we were only able to assess 13/191 genes. COBL encodes an actin
regulator protein, and the Vangl2Lp/CoblC101/C101 mutant mice show
exencephaly, indicating an interaction between these genes.45 FAT4
encodes a protocadherin family protein that is associated with the
PCP pathway.46 A study of Fat4-null mice described impaired conver-
gent extension with faulty ureteric tubule elongation.46 However, in
humans, mutations in this gene are implicated in both Van Malder-
gem Syndrome 2 [OMIM: 615546], characterized by intellectual dis-
ability with typical craniofacial features, and Hennekam
Lymphangiectasia-Lymphedema Syndrome 2 [OMIM: 616006], which
causes lymphatic dysplasia.
4.5 | Study limitations
No parental samples were available for this study, excluding the possi-
bility of identifying de novo mutations or evaluating penetrance or co-
inheritance of risk alleles from each parent. Due to the lethality of this
phenotype, it is also difficult to ascertain familial anencephalic cases.
Only DNA was available which excluded the possibility of testing
gene/protein expression associations with the variants. As a candidate
gene approach, we were unable to comprehensively include all genes
that could be implicated in NTD causation. This can more easily be
achieved using whole exome/genome sequencing (WES/WGS) in a
hypothesis-free manner. However, recent WES studies32,47 have still
focused on analysis of known candidate genes. Our data and findings
of these other studies concur that no major recurring genetic defect
explains any substantial group of NTDs, consistent with the notion
that all NTD types are most likely complex traits involving interaction
of multiple loci and non-genetic factors. It remains possible that sub-
stantial genetic contributions come from outside the coding regions,
which would also be missed in WES. Future investigations will need to
include non-coding regulatory regions (eg, enhancers), using WES for
more comprehensive analysis. However, identification of causal vari-
ants can be even more challenging at this level. For the moment the
authenticity of reported human NTD mutations still needs to be
unequivocally verified. Although functional analysis was beyond the
scope of this study, it would be of great benefit to test candidate vari-
ants in mouse models to provide confirmation of causal effect.
5 | CONCLUSION AND FUTURE STUDIES
We have identified novel and rare variants within genes with known
biological association with NTDs, specifically focusing on folate
metabolism and PCP pathways. This study highlights the potential
involvement of PCP genes including CELSR1 in association with anen-
cephaly phenotypes, and also PDGFRA as strong NTD candidates in
humans. Further identification and functional testing of genetic fac-
tors will lead to improved understanding of molecular mechanisms of
NTD, and ultimately may help to create a targeted and cost-effective
method of screening genes for the clinical management of families
with a history of NTD-affected pregnancy.
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